CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) CEO Thomas P. Mathers sold 1,502 shares of the stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $37.08, for a total value of $55,694.16. Following the transaction, the chief executive officer now directly owns 248,169 shares in the company, valued at approximately $9,202,106.52. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) opened at 36.96 on Thursday. The company has a 50-day moving average price of $22.05 and a 200 day moving average price of $11.05. The firm’s market capitalization is $566.74 million. CoLucid Pharmaceuticals Inc. has a one year low of $3.60 and a one year high of $39.27.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last posted its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.22. Analysts expect that CoLucid Pharmaceuticals Inc. will post ($3.91) earnings per share for the current fiscal year.
A number of brokerages have weighed in on CLCD. Piper Jaffray Cos. set a $49.00 price target on CoLucid Pharmaceuticals and gave the stock an “overweight” rating in a research note on Friday, September 30th. Ladenburg Thalmann set a $57.00 price target on CoLucid Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, September 19th. Stifel Nicolaus increased their price target on CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, September 19th. Finally, Zacks Investment Research lowered CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 9th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. CoLucid Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $33.05.
Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC acquired a new position in CoLucid Pharmaceuticals during the second quarter valued at about $554,000. Vanguard Group Inc. raised its position in CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 900 shares during the period. Finally, Societe Generale acquired a new position in CoLucid Pharmaceuticals during the second quarter valued at about $464,000. Hedge funds and other institutional investors own 30.47% of the company’s stock.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.